| Report | Options implied | Actual move | Market was |
|---|---|---|---|
| 07/30/2026 | ±2.4% | +2.8% | under-priced |
| 10/30/2025 | ±1.5% | +7.1% | under-priced |
| 07/31/2025 | ±2.7% | -5.8% | under-priced |
| 04/24/2025 | ±3.1% | +0.3% | over-priced |
| 10/31/2024 | ±1.7% | +5.9% | under-priced |
| 04/25/2024 | ±1.4% | -8.5% | under-priced |
| 10/26/2023 | ±1.6% | -6.4% | under-priced |
| Quarter | EPS (dil.) | Revenue | Net income |
|---|---|---|---|
| Q2 FY2026 | $1.62 | $13.0B | $3.3B |
| Q1 FY2026 | $1.31 | $11.5B | $2.7B |
| Q4 FY2025 | $0.53 | $12.5B | $1.1B |
| Q3 FY2025 | $1.08 | $12.2B | $2.2B |
Bristol-Myers Squibb Co. (BMY) reports in 115 days, with the next report estimated for 01/05/2027. Across the last 7 reports, options priced an average ±2.0% earnings move while the stock actually moved 5.3% on average — the market has tended to under-price BMY's earnings risk. Fundamentals into the print: EPS up 153.1% year-over-year, revenue up 5.7%. QuantLogix's live 5-factor engine currently reads BMY as a buy at 62/100.
Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →